Telix Pharmaceuticals Ltd. has announced that its prostate cancer imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has received marketing authorization from the Austrian Medicines and Medical Devices Agency $(BASG)$. This approval allows healthcare providers in Austria to utilize PSMA-PET imaging for detecting and localizing prostate-specific membrane antigen-positive lesions in adults with prostate cancer. The decision is based on comprehensive clinical data, including findings from the VISION trial. Illuccix will be distributed in Austria by THP Medical Products, enabling wider access to this advanced diagnostic tool in a country where prostate cancer is the most prevalent cancer among men.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.